CG Oncology, Inc. financial data

Symbol
CGON on Nasdaq
Location
400 Spectrum Center Drive, Suite 2040, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.69K % -26.3%
Debt-to-equity 4.23 % +24%
Return On Equity -21.7 % -14.2%
Return On Assets -20.8 % -35.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80.7M shares +19.3%
Common Stock, Shares, Outstanding 78.3M shares +15.9%
Entity Public Float 1.4B USD
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 76.7M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 76.7M shares +14.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 113M USD +58.4%
General and Administrative Expense 67.2M USD +169%
Operating Income (Loss) -180M USD -87.7%
Nonoperating Income (Expense) 28.6M USD +23.6%
Net Income (Loss) Attributable to Parent -151M USD -108%
Earnings Per Share, Basic -2 USD/shares +62.7%
Earnings Per Share, Diluted -2 USD/shares +62.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.1M USD +3.99%
Marketable Securities, Current 635M USD +27.7%
Inventory, Net 1.5M USD
Assets, Current 696M USD +26%
Property, Plant and Equipment, Net 15.3M USD +24232%
Operating Lease, Right-of-Use Asset 4.2M USD +1428%
Goodwill 12.8M USD
Other Assets, Noncurrent 114K USD +115%
Assets 730M USD +32.1%
Accounts Payable, Current 9.19M USD +126%
Liabilities, Current 30.5M USD +95.3%
Operating Lease, Liability, Noncurrent 3.33M USD +4589%
Other Liabilities, Noncurrent 3.8M USD
Liabilities 42.3M USD +169%
Retained Earnings (Accumulated Deficit) -338M USD -81.4%
Stockholders' Equity Attributable to Parent 688M USD +28.1%
Liabilities and Equity 730M USD +32.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3M USD -12.6%
Net Cash Provided by (Used in) Financing Activities 450K USD -99.9%
Net Cash Provided by (Used in) Investing Activities -187M USD +39.3%
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 78.3M shares +15.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -216M USD -412%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.1M USD +3.99%
Deferred Tax Assets, Valuation Allowance 56.4M USD +85.2%
Deferred Tax Assets, Gross 56.5M USD +84.8%
Operating Lease, Liability 4.24M USD +1333%
Depreciation 500K USD
Payments to Acquire Property, Plant, and Equipment 16K USD +33.3%
Lessee, Operating Lease, Liability, to be Paid 4.91M USD +1542%
Property, Plant and Equipment, Gross 16M USD
Operating Lease, Liability, Current 912K USD +305%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.14M USD +2087%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.16M USD +521%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +307%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 668K USD +22167%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.12M USD
Deferred Tax Assets, Operating Loss Carryforwards 34.6M USD +92.1%
Unrecognized Tax Benefits 1.4M USD +39.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.04M USD
Operating Lease, Payments 443K USD +101%
Additional Paid in Capital 1.03B USD +41.8%
Depreciation, Depletion and Amortization 24K USD +500%
Deferred Tax Assets, Net of Valuation Allowance 56.4M USD +85.2%
Share-based Payment Arrangement, Expense 24.5M USD +240%